European Journal of Cardiovascular Medicine

Objective: Several new or repositioned drugs have been tried in covid19, but none have been shown to be efficacious. This observational study was carried out because previous data showing effect of remdesivir in treatment of moderate to severe covid19 patients were controversial. Method: A retrospective analysis was carried out of moderate to severe covid19 patients with SpO2 level<94% admitted in hospital after approval of the ethics committee. Patients were divided in 2 groups according to treatment received, standard treatment (Group A) or standard treatment + remdesivir (group B). Purpose of the study was to determine the difference in term of final outcome (death or recovered), change in SpO2 level, average hospitalization duration and change in laboratory values between both group. Results: There were total 1193 covid19 patients (group A: 1044 patients; group B: 149 patients). No significant difference observed in final outcome [death in group A(43.29%), group B(42.28%), P=0.88]. Adding remdesivir to standard treatment significantly reduced hospitalization duration in those recovered (P=0.0025) and improved SpO2 level significantly between day 1-5(P=0.0002), 1-10(P<0.0001) and 1-14(P=0.0001). Conclusions: We concluded that adding remdesivir in the standard treatment of the patients did not improve the final outcome (prevention of death) of the disease